Histiocytosis Clinical Trial
Official title:
Enquête épidémiologique Sur la prévalence et le Pronostic de l'Histiocytose Langerhansienne Pulmonaire de l'Adulte en France
The long-term outcomes of adult patients with pulmonary Langerhans cell histiocytosis (PLCH), particularly survival, is largely unknown. This is the first prospective study in the field evaluating the long-term outcomes of PLCH patients. This french countrywide registry-based study included a large cohort of PLCH patients followed for a sufficiently long period to address risk factors of long-term outcomes of PLCH patients.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | December 31, 2035 |
Est. primary completion date | December 31, 2034 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age >= 18 years - Diagnosis of PLCH was either histologically confirmed on a biopsy of an involved tissue, or based on the combination of the following criteria: 1) an appropriate clinical picture; 2) a typical nodulo-cystic pattern on lung high-resolution computed tomography (HRCT) and 3) exclusion of alternative diagnoses Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
France | French national reference centre for Histiocytoses | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival | Overall survival defined as the time from inclusion to death from any cause. | 20 years | |
Secondary | CRF | Cumulative incidence of chronic respiratory failure (CRF) from inclusion | 20 years | |
Secondary | PH | Cumulative incidence of pulmonary hypertension (PH) from inclusion | 20 years | |
Secondary | Malignant diseases | Cumulative incidence of Malignant diseases from inclusion | 20 years | |
Secondary | Extra-pulmonary involvement in isolated PLCH | Cumulative incidence of extra pulmonary localisations from inclusion | 20 years | |
Secondary | Annual prevalence | Number of people with the disease at any time during a year | 20 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01049854 -
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
|
Phase 2 | |
Recruiting |
NCT05915208 -
Histiocytic Disorder Follow-up Study
|
||
Recruiting |
NCT04437381 -
Molecular Targets for the Treatment of Histiocytosis
|
||
Terminated |
NCT01050439 -
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
|
Phase 2 | |
Active, not recruiting |
NCT00145626 -
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT05803629 -
Characterizing Histiocytosis With 68Ga-FAPI PET/CT
|
N/A | |
Terminated |
NCT02012231 -
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
|
Phase 1 | |
Completed |
NCT01225718 -
Ceftriaxone in Non-neutropenic Fever
|
N/A | |
Active, not recruiting |
NCT03127709 -
A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis
|
||
Recruiting |
NCT05786924 -
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
|
Phase 1 | |
Recruiting |
NCT04943198 -
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
|
Phase 2 | |
Recruiting |
NCT04943224 -
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
|
Phase 2 | |
Recruiting |
NCT04943211 -
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
|
Phase 3 |